Literature DB >> 6540145

Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats.

N M Osman, M P Copley, C L Litterst.   

Abstract

Renal toxicity following a single iv nonlethal dose (6 mg/kg) of cisplatin (CDDP) was investigated in male F344 rats pretreated with 20 mg/kg of acetazolamide (ACZ) sc 30 minutes before CDDP administration. There was a decrease in nephrotoxicity as indicated by a smaller elevation of BUN, a milder histopathologic lesion, and a more rapid recovery of BUN in ACZ-pretreated animals. Renal platinum content of rats receiving ACZ was significantly lower than that in animals treated with CDDP alone. There was no change in platinum level in the plasma or the liver but there was a decreased platinum excretion in urine during 24 hours after treatment. Reduction of platinum concentration in the kidney might account for protection against the renal toxicity. The diuretic ACZ might be useful in the hydration regimens used clinically to prevent renal toxicity from CDDP.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540145

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  16 in total

1.  Acute cisplatin nephrotoxicity in the rat. Evidence for impaired entry of sodium into proximal tubule cells.

Authors:  M J Field; T E Bostrom; F Seow; A Z Györy; D J Cockayne
Journal:  Pflugers Arch       Date:  1989-09       Impact factor: 3.657

Review 2.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

3.  Cisplatin induces modulation of transferrin receptor during cellular differentiation in vitro.

Authors:  G P Tonini; M T Parodi; R Bologna; P Persici; P Cornaglia-Ferraris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Control of some aspects of cis-platinum nephrotoxicity.

Authors:  M M Jones; M A Basinger; W D Craft; J L Domingo; J M Llobet
Journal:  Arch Toxicol       Date:  1986-10       Impact factor: 5.153

Review 5.  Clinical management of cytotoxic drug overdose.

Authors:  L L Thomas; M J Mertens; A E von dem Borne; C J van Boxtel; C H Veenhof; E P Veies
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jul-Aug

6.  Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats.

Authors:  N M Osman; M P Copley; C L Litterst
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).

Authors:  J Kralovánszky; N Prajda; S Kerpel-Fronius; F Gál; F Kiss
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 9.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Inhibition of cis-diamminedichloroplatinum (II)--induced renal toxicity in the rat.

Authors:  M M Jones; M A Basinger; W M Mitchell; C A Bradley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.